683 Capital Management LLC Invests $630,000 in Rezolute, Inc. (NASDAQ:RZLT)

683 Capital Management LLC acquired a new position in shares of Rezolute, Inc. (NASDAQ:RZLT - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 128,668 shares of the company's stock, valued at approximately $630,000. 683 Capital Management LLC owned about 0.22% of Rezolute at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. JPMorgan Chase & Co. purchased a new stake in shares of Rezolute in the third quarter valued at about $42,000. Charles Schwab Investment Management Inc. raised its stake in Rezolute by 65.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company's stock valued at $112,000 after purchasing an additional 9,000 shares in the last quarter. Virtu Financial LLC increased its position in shares of Rezolute by 58.0% during the 3rd quarter. Virtu Financial LLC now owns 26,026 shares of the company's stock valued at $126,000 after purchasing an additional 9,551 shares during the last quarter. Alpine Global Management LLC purchased a new stake in shares of Rezolute during the fourth quarter valued at approximately $54,000. Finally, State Street Corp increased its holdings in Rezolute by 11.6% during the 3rd quarter. State Street Corp now owns 125,472 shares of the company's stock valued at $609,000 after purchasing an additional 13,000 shares during the period. Institutional investors own 82.97% of the company's stock.

Analyst Upgrades and Downgrades

RZLT has been the subject of a number of analyst reports. Craig Hallum raised Rezolute to a "strong-buy" rating in a research report on Tuesday, February 4th. Guggenheim reiterated a "buy" rating on shares of Rezolute in a report on Monday, February 10th. JMP Securities boosted their price target on shares of Rezolute from $8.00 to $9.00 and gave the stock a "market outperform" rating in a research report on Thursday, February 13th. Finally, HC Wainwright reiterated a "buy" rating and issued a $14.00 target price on shares of Rezolute in a report on Monday, April 28th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $26.43.

Insider Transactions at Rezolute

In other news, Director Wladimir Hogenhuis bought 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was purchased at an average price of $4.70 per share, with a total value of $47,000.00. Following the completion of the acquisition, the director now directly owns 77,267 shares of the company's stock, valued at $363,154.90. This trade represents a 14.87 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Nevan C. Elam purchased 12,302 shares of the stock in a transaction on Thursday, March 27th. The stock was acquired at an average cost of $2.85 per share, for a total transaction of $35,060.70. Following the completion of the acquisition, the chief executive officer now owns 224,119 shares of the company's stock, valued at $638,739.15. The trade was a 5.81 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 39,060 shares of company stock valued at $130,694. Corporate insiders own 18.39% of the company's stock.

Rezolute Trading Up 3.0 %

Shares of Rezolute stock traded up $0.12 on Monday, hitting $4.12. 1,166,100 shares of the company traded hands, compared to its average volume of 605,603. The company has a market cap of $249.40 million, a PE ratio of -3.38 and a beta of 1.01. Rezolute, Inc. has a 52 week low of $2.22 and a 52 week high of $6.19. The stock's 50 day moving average price is $3.30 and its 200-day moving average price is $4.41.

Rezolute (NASDAQ:RZLT - Get Free Report) last posted its earnings results on Wednesday, February 12th. The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.11. As a group, research analysts anticipate that Rezolute, Inc. will post -0.93 EPS for the current fiscal year.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.